212 related articles for article (PubMed ID: 32588888)
1. Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice.
Jaini R; Loya MG; King AT; Thacker S; Sarn NB; Yu Q; Stark GR; Eng C
Hum Mol Genet; 2020 Aug; 29(14):2353-2364. PubMed ID: 32588888
[TBL] [Abstract][Full Text] [Related]
2. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Chen HH; Händel N; Ngeow J; Muller J; Hühn M; Yang HT; Heindl M; Berbers RM; Hegazy AN; Kionke J; Yehia L; Sack U; Bläser F; Rensing-Ehl A; Reifenberger J; Keith J; Travis S; Merkenschlager A; Kiess W; Wittekind C; Walker L; Ehl S; Aretz S; Dustin ML; Eng C; Powrie F; Uhlig HH
J Allergy Clin Immunol; 2017 Feb; 139(2):607-620.e15. PubMed ID: 27477328
[TBL] [Abstract][Full Text] [Related]
3. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.
Mester JL; Tilot AK; Rybicki LA; Frazier TW; Eng C
Eur J Hum Genet; 2011 Jul; 19(7):763-8. PubMed ID: 21343951
[TBL] [Abstract][Full Text] [Related]
4. Dynamics and structural stability effects of germline PTEN mutations associated with cancer versus autism phenotypes.
Smith IN; Thacker S; Jaini R; Eng C
J Biomol Struct Dyn; 2019 Apr; 37(7):1766-1782. PubMed ID: 29663862
[TBL] [Abstract][Full Text] [Related]
5. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
[TBL] [Abstract][Full Text] [Related]
6. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
Ngeow J; Eng C
Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
[TBL] [Abstract][Full Text] [Related]
7. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
Orloff MS; Eng C
Oncogene; 2008 Sep; 27(41):5387-97. PubMed ID: 18794875
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J; Sesock K; Eng C
Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
[TBL] [Abstract][Full Text] [Related]
9. Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome.
Sloot YJE; Rabold K; Netea MG; Smit JWA; Hoogerbrugge N; Netea-Maier RT
Oncogene; 2019 May; 38(19):3743-3755. PubMed ID: 30670777
[TBL] [Abstract][Full Text] [Related]
10. Cowden syndrome.
Gustafson S; Zbuk KM; Scacheri C; Eng C
Semin Oncol; 2007 Oct; 34(5):428-34. PubMed ID: 17920899
[TBL] [Abstract][Full Text] [Related]
11. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
[TBL] [Abstract][Full Text] [Related]
12. Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome".
Galatola M; Paparo L; Duraturo F; Turano M; Rossi GB; Izzo P; De Rosa M
BMC Med Genet; 2012 Apr; 13():28. PubMed ID: 22520842
[TBL] [Abstract][Full Text] [Related]
13. The Role of PTEN in Innate and Adaptive Immunity.
Taylor H; Laurence ADJ; Uhlig HH
Cold Spring Harb Perspect Med; 2019 Dec; 9(12):. PubMed ID: 31501268
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
[TBL] [Abstract][Full Text] [Related]
15. Cerebellar phenotypes in germline PTEN mutation carriers.
Gambini D; Ferrero S; Bulfamante G; Pisani L; Corbo M; Kuhn E
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12970. PubMed ID: 38504418
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications for Germline PTEN Spectrum Disorders.
Ngeow J; Sesock K; Eng C
Endocrinol Metab Clin North Am; 2017 Jun; 46(2):503-517. PubMed ID: 28476234
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.
Rodríguez-Escudero I; Oliver MD; Andrés-Pons A; Molina M; Cid VJ; Pulido R
Hum Mol Genet; 2011 Nov; 20(21):4132-42. PubMed ID: 21828076
[TBL] [Abstract][Full Text] [Related]
18. PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation?
Yehia L; Eng C
Hum Mol Genet; 2020 Oct; 29(R2):R150-R157. PubMed ID: 32568377
[TBL] [Abstract][Full Text] [Related]
19. Imaging of PTEN-related abnormalities in the central nervous system.
Dhamija R; Hoxworth JM
Clin Imaging; 2020 Apr; 60(2):180-185. PubMed ID: 31927175
[TBL] [Abstract][Full Text] [Related]
20. Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity.
Laury AR; Bongiovanni M; Tille JC; Kozakewich H; Nosé V
Thyroid; 2011 Feb; 21(2):135-44. PubMed ID: 21190448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
